HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Merrick, M. V. Articles by Ross, H. McL. Search for Related Content PubMed PubMed Citation Articles by Merrick, M. V. Articles by Ross, H. McL.

Enterohepatic Circulation in Man of a Gamma-Emitting Bile-Acid Conjugate,23-Selena-25-Homotaurocholic Acid (SeHCAT)

Wolfson Laboratories, Western General Hospital, Edinburgh, Scotland

ABSTRACT

A conjugated bile acid, 23-selena-25-homotaurocholic acid (SeHCAT), labeled with the gamma emitter Se-75, has been evaluated in man. Absorption and excretion were compared with that of simultaneously administered [23-¹⁴C]cholic acid. SeHCAT is absorbed quantitatively following oral administration, secreted into the bile at the same rate as cholic acid, reabsorbed from the small intestine, and resecreted. It is not absorbed when the terminal ileum has been excised or bypassed. SeHCAT is therefore the first of a new class of radiopharmaceuticals, namely, gamma-emitting tracers of the complete cycle of the enterohepatic circulation. Its use will simplify investigation of the functional state of the terminal ileum by eliminating the need to collect and process feces.

This article has been cited by other articles:

				A Lanzini, M G De Tavonatti, B Panarotto, S Scalia, A Mora, F Benini, O Baisini, and F Lanzarotto Intestinal absorption of the bile acid analogue 75Se-homocholic acid-taurine is increased in primary biliary cirrhosis, and reverts to normal during ursodeoxycholic acid administration Gut, September 1, 2003; 52(9): 1371 - 1375. [Abstract] [Full Text]